Regal Partners (RPL) is held by 6 ASX ETFs as of 15 Oct 2026. It weighs most in ISO, at 0.2% of the fund. Over the last year it fell 39.7%: on $10,000, −$3971. We explain 5 big moves in that time.
About RPL
- SectorFinancials
- IndustryFinancial Services
- Size$894.8m
- Held by6 ETFs
- Big moves5 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- −4.7%peak −6.2%28 Aug 2026· Management
Regal Partners shares fell as markets continued to digest the surprise retirement of founder and star fund manager Phil King, announced on 24 August, raising concerns about key-person risk and future performance.
- −2.8%peak −10.0%24 Aug 2026· Sector Flow
RPL.AX fell as part of a broad sell-off across the ASX Financials sector, with no company-specific news to explain the move.
- +5.7%31 Mar 2026· Unknown
Stock appeared in multiple penny stock watchlists around the event date, potentially triggering retail buying interest.
- −5.2%13 Mar 2026· Unknown
No specific news explains the drop; likely broad market or sector-driven movement.
- +5.7%19 Dec 2025· Unknown
Insufficient evidence to determine the cause of the price move
Held by 6 ETFs
Of every $10,000 in each fund, how much is in RPL today.
- ISOiShares S&P/ASX Small Ordinaries ETF$230.23%
- SSOSTATE STREET SPDR S&P/ASX SMALL ORDINARIES ETF$220.22%
- IHDiShares S&P/ASX Dividend Opportunities ESG Screened ETF$110.11%
- VETHVanguard Ethically Conscious Australian Shares ETF$2.510.03%
- VASVanguard Australian Shares Index ETF$2.320.02%
- A300Global X Australia 300 ETF$2.120.02%
Other Financials companies
- IAGInsurance Aus.63 ETFs
- AMPAMP56 ETFs
- ANZANZ Group51 ETFs
- NABNat. Aus. Bank49 ETFs
- BENBendigo46 ETFs
- SUNSuncorp42 ETFs
- HUMHumm39 ETFs
- WBCWestpac38 ETFs
Why did RPL fall 14.8% on 24 Mar 2025?
Regal Partners
Regal Partners' listed funds slashed the value of biotech Opthea by two-thirds after a clinical trial failure, causing investor concern over the impact on Regal's funds.
The news articles directly link the price move to investor concern over a clinical trial failure and a subsequent two-thirds valuation cut of Opthea, a portfolio holding. This is an operational update affecting the company's asset values, not a result of its own earnings or guidance.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
News coverage
What it did to the 6 ETFs holding RPL
On $10,000 in each fund, at the weight it holds today